🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#EBMT25 The JACIE team is here in Florence! 🌍Visit our booth to get updates on the latest JACIE developments, meet our members and ask your accreditation-related questions. 📍 Find us together at the EBMT Booth and come say hello! 👋

CONGRESS | #EBMT25 The EBMT | PRESENTATION Vera Radici, Università degli Studi di Brescia, presents interim results from the phase II FT14 study evaluating the safety and efficacy of fludarabine plus myeloablative dose of treosulfan conditioning regimen before HSCT in 62 patients with AML aged

Congratulations to the 2025 Jon J. van Rood Award winners Janaki Manoja Vinnakota (pictured) and Nicoletta Cieri! 👏 Read the recent interview as the winners speak on their individual, highly commended abstracts that were presented this morning at the EBMT_Cellular_Therapy Session at

Fascinating and high-quality debate at the Lymphoma Working Party Session on CAR-T vs. auto-HSCT for chemosensitive DLBCL in first relapse. Kudos to Anna Ossami Saidy and Chris Fox for engaging the audience in a lively discussion with many great questions! #EBMT25 The EBMT

EBMT 2025 Election Results are in! 📣 #EBMT25 🎉 Congratulations to Ibrahim Yakoub-Agha, named EBMT President-Elect, as he embarks on a one-year transition, alongside Anna Sureda. A big welcome also to our new EBMT Working Party Chairs: 👤 Maria Ester Bernardo - EBMT Inborn

Honored to present our latest #RomeeLab research on engineering IL-12-secreting CAR NK cells to target high-risk AML—demonstrating feasibility, safety, and efficacy. What a pleasure to be at #EBMT25 in Florence! 🇮🇹🌞 Rizwan Romee The EBMT

So proud of Magdalena Corona for receiving the Jian-Jian Luan Award The EBMT and presenting our work on multiomic CD19 profiling pre- and post- #CART in LBCL #EBMT25 #Lymphona Memorial Sloan Kettering Cancer Center

Thank you… it was a pleasure to discuss an important question with a high quality opponent and an expert audience! The EBMT

Outstanding talk by Rizwan Romee on harnessing innate NK cell memory in high-risk AML/MDS, highlighting promising clinical trials results and future directions. #EBMT25

Démagogie politique qui va réduire encore plus l’offre de soins et de façon injuste envers les étudiants en médecine. Ne lâchez rien les internes, externes et jeunes seniors !!!

Please check out our paper published in Nature Medicine on our Phase I trial of AFM13-precomplexed cord blood NK cells in relapsed/refractory CD30+ lymphomas. Led by Dr. Yago Nieto and an outstanding team of coauthors and collaborators, this study marks the first clinical

“No government—regardless of which party is in power—should dictate what private universities can teach, whom they can admit and hire, and which areas of study and inquiry they can pursue.” - President Alan Garber hrvd.me/GarberRespond3…

Excited to share our review on CAR arming of the innate immune cells. Engineering innate immune cells for cancer immunotherapy | Nature Biotechnology nature.com/articles/s4158…

Thank you VJHemOnc for giving me the opportunity to discuss the findings of our recent publication in Nature Medicine: nature.com/articles/s4159… #CARTcell #EBMT25 Lysa Lymphoma

🚨 Check out our new grading system for thrombocytopenia (#T_ICAHT) after #CART doi.org/10.1182/blood.… Blood Journal Led by Drs. Kai Rejeski, Jaime Sanz, Teng Fei & team — incredible multicenter collaborative effort. See Kai’s 🧵for more insights!

Happy to participate to the 15th Forum for Cellular and Humoral Immunotherapy today at 4pm CET. I will discuss the risks of secondary malignancy after #CARTcell therapy. Feel free to register👉 us06web.zoom.us/webinar/regist…

Very happy to share our work on therapy-related myeloid neoplasms (t-MN) post-CD19 CAR T-cell therapy, published in Leukemia Journal and involving 4 French centers (CHU de Lille, Lyon, Caen, St-Étienne). 🔗 doi.org/10.1038/s41375… #CAR_T #Lymphoma #tMN #Hematology

CONGRESS | #18ICML | PRESENTATION Ali Bazarbachi discusses an analysis from the EBMT Lymphoma Working Party of outcomes following CAR-T versus auto-HSCT in patients with large B-cell lymphoma in CR. There were no significant differences between CAR-T and auto-HSCT for OS, PFS,

Excited to participate to this upcoming IACH webinar! #lymsm #EHA2025 #18ICML #ASCO #EBMT25 Join us 👇👇👇

📢 𝗪𝗲 𝗮𝗿𝗲 𝗟𝗜𝗩𝗘 𝗜𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝗶𝗻 𝗹𝘆𝗺𝗽𝗵𝗼𝗺𝗮: 𝘂𝗽𝗱𝗮𝘁𝗲 𝗳𝗿𝗼𝗺 𝘁𝗵𝗲 𝗹𝗮𝘁𝗲𝘀𝘁 𝗰𝗼𝗻𝗴𝗿𝗲𝘀𝘀𝗲𝘀 🆓 𝗙𝗿𝗲𝗲 𝗿𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻 𝗵𝗲𝗿𝗲 ⤵️ us06web.zoom.us/webinar/regist… Rémy Duléry Mohamad Mohty